Pasar al contenido principal

PRODUCCION Y VALIDACION DE FARMACOS BASADOS EN PEPTIDOS DE DEFENSA DEL HUESPED PARA EL TRATAMIENTO DEL SINDROME RESPIRATORIO BOVINO

PID2019-107298RB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA I TECNOLOGIA AGROALIMENTARIES (IRTA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Structure–Antimicrobial Activity Relationships of Recombinant Host Defence Peptides Against Drug-Resistant Bacteria

  • Travé-Asensio, Sergi
  • Tort-Miró, Aida
  • Pinheiro, Silvana
  • Garcia-Fruitos, Elena
  • Arís, Anna
  • Zamora, William J.
Host defence peptides (HDPs) represent a valuable class of antimicrobial agents with the potential to address the growing threat of antimicrobial resistance (AMR). Here, we have studied recombinant constructs based on a combination of HDPs fused to the GFP protein and multidomain proteins combining three or four HDPs in a single polypeptide, referred to as first and second generation antimicrobials, respectively. These recombinant peptides were tested against Gram-positive and Gram-negative bacteria associated with healthcare infections. In addition, in silico studies provided insight into the antimicrobial structure–activity relationships of these biomolecules. For the first generation of antimicrobials, amphipathicity mainly explains the average antimicrobial activity against the Gram-positive strains. In the case of the Gram-negative bacteria, it depends on the quantity and the exposed area of the Ser and Thr amino acids. For the second generation of antimicrobials, the order of domains is crucial to act against Gram-positive strains, preferably by positioning the most bioactive domain against the Gram-positive pathogen at the ends., This work was supported by the AGAUR (Generalitat de Catalunya), 2021SGR01552, Ministerio de Universidades, FPU21/04977, Ministerio de Ciencia, Innovación y Universidades, PID2019-107298RB-C21/AEI/10.13039/501100011033, PID2022-136521OB-I00 and Vice Chancellor for Research of the University of Costa Rica, 115-C1-450., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

The future of recombinant host defense peptides

  • Roca-Pinilla, Ramon
  • Lisowski, Leszek
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
The antimicrobial resistance crisis calls for the discovery and production of new antimicrobials. Host defense peptides (HDPs) are small proteins with potent antibacterial and immunomodulatory activities that are attractive for translational applications, with several already under clinical trials. Traditionally, antimicrobial peptides have been produced by chemical synthesis, which is expensive and requires the use of toxic reagents, hindering the large-scale development of HDPs. Alternatively, HDPs can be produced recombinantly to overcome these limitations. Their antimicrobial nature, however, can make them toxic to the hosts of recombinant production. In this review we explore the different strategies that are used to fine-tune their activities, bioengineer them, and optimize the recombinant production of HDPs in various cell factories., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Exploring the impact of the recombinant Escherichia coli strain on defensins antimicrobial activity: BL21 versus Origami strain

  • López-Cano, Adrià
  • Martínez-Miguel, Marc
  • Guasch, Judith
  • Ratera, Imma
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
The growing emergence of microorganisms resistant to antibiotics has prompted the development of alternative antimicrobial therapies. Among them, the antimicrobial peptides produced by innate immunity, which are also known as host defense peptides (HDPs), hold great potential. They have been shown to exert activity against both Gram-positive and Gram-negative bacteria, including those resistant to antibiotics. These HDPs are classified into three categories: defensins, cathelicidins, and histatins. Traditionally, HDPs have been chemically synthesized, but this strategy often limits their application due to the high associated production costs. Alternatively, some HDPs have been recombinantly produced, but little is known about the impact of the bacterial strain in the recombinant product. This work aimed to assess the influence of the Escherichia coli strain used as cell factory to determine the activity and stability of recombinant defensins, which have 3 disulfide bonds. For that, an α-defensin [human α-defensin 5 (HD5)] and a β-defensin [bovine lingual antimicrobial peptide (LAP)] were produced in two recombinant backgrounds. The first one was an E. coli BL21 strain, which has a reducing cytoplasm, whereas the second was an E. coli Origami B, that is a strain with a more oxidizing cytoplasm. The results showed that both HD5 and LAP, fused to Green Fluorescent Protein (GFP), were successfully produced in both BL21 and Origami B strains. However, differences were observed in the HDP production yield and bactericidal activity, especially for the HD5-based protein. The HD5 protein fused to GFP was not only produced at higher yields in the E. coli BL21 strain, but it also showed a higher quality and stability than that produced in the Origami B strain. Hence, this data showed that the strain had a clear impact on both HDPs quantity and quality., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Design strategies for positively charged endolysins: Insights into Artilysin development

  • Carratalá, Jose Vicente
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
  • Ferrer-Miralles, Neus
Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature., The authors are indebted to Agencia Española de Investigación for the granted project (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EGF and AA and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NFM), to Marató de TV3 foundation (grant 201812-30-31-32-33) and to AGAUR for project 2021 SGR 01552. The authors are also indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. JVCT is supported with a Margarita Salas grant for the training of young doctoral graduates (722713)., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Quality comparison of recombinant soluble proteins and proteins solubilized from bacterial inclusion bodies

  • López-Cano, Adrià
  • Sicilia, Paula
  • Gaja, Clara
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
Recombinant protein production in bacteria is often accompanied by the formation of aggregates, known as inclusion bodies (IBs). Although several strategies have been developed to minimize protein aggregation, many heterologous proteins are produced in aggregated form. For these proteins, purification necessarily requires processes of solubilization and refolding, often involving denaturing agents. However, the presence of biologically active recombinant proteins forming IBs has driven a redefinition of the protocols used to obtain soluble protein avoiding the protein denaturation step. Among the different strategies described, the detergent n-lauroylsarcosine (NLS) has proved to be effective. However, the impact of the NLS on final protein quality has not been evaluated so far. Here, the activity of three antimicrobial proteins (all as GFP fusions) obtained from the soluble fraction was compared with those solubilized from IBs. Results showed that NLS solubilized proteins from IBs efficiently, but that protein activity was impaired. Thus, a solubilization protocol without detergents was evaluated, demonstrating that this strategy efficiently solubilized proteins embedded in IBs while retaining their biological activity. These results showed that the protocol used for IB solubilization has an impact on final protein quality and that IBs can be solubilized through a very simple step, obtaining fully active proteins., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Exploring the therapeutic potential of recombinant bovine β-defensins for antimicrobial and anti-inflammatory functions in sepsis management

  • Saubi, Cristina
  • Baltà-Foix, Ricardo
  • Carratalá, Jose Vicente
  • Fàbregas, Francesc
  • Sandín, Daniel
  • Torrent, Marc
  • Garcia-Fruitos, Elena
  • Arís, Anna
β-defensins are multifunctional peptides of the host immune system involved in responses to infectious diseases. We investigated the potential of five recombinant proteins based on bovine β-defensins (bovine neutrophil β-defensins (BNBD) 1, 2, 3, and 4, and the tracheal antimicrobial peptide (TAP)) in functions relevant to sepsis such as antimicrobial activity, lipopolysaccharide (LPS) binding and neutralisation, and the stimulation of cytokine response in epithelial cells. These β-defensins were produced in Lactococcus lactis as fusion proteins. Antimicrobial activity was tested against Escherichia coli; LPS binding and neutralisation were assessed using a fluorescent probe displacement assay and by measuring tumour necrosis factor alpha (TNFα) levels in whole blood after an LPS challenge, respectively. Interleukin-8 (IL-8) levels were quantified to evaluate the epithelial immune response. All β-defensins exhibited different properties, suggesting they may have distinct mechanisms and functions in resolving infections. The recombinant BNBD4 showed potent antimicrobial activity against E. coli, whereas TAP was more notable for its ability to bind and neutralise LPS. These findings suggest that β-defensins, particularly BNBD4 and TAP, may be utilised to treat sepsis by targeting bacterial pathogens and modulating inflammatory responses., This work was funded by Ministerio de Ciencia, Innovación y Universidades Grants PID2019-107298RB-C21/AEI/10.13039/ 501100011033) to AA and EG-F and by MICIU/AEI/10.13039/ 501100011033 and FEDER with project PID2023-152706OB-I00. CS and RB-F received a pre-doctoral fellowship from Generalitat de Catalunya (FI-AGAUR and INIA (FPI-INIA, MINECO), respectively. DS received a pre-doctoral fellowship PRE2018-083243 from Ministerio de Ciencia, Innovación y Universidades. JVC was supported with a Margarita Salas grant for the training of young doctoral graduates (Grant No. 722713)., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria

  • Carratalá, Jose Vicente
  • Ferrer‐Miralles, Neus
  • Garcia-Fruitos, Elena
  • Arís, Anna
Antimicrobial resistance (AMR) is an escalating global health crisis, driven by the overuse and misuse of antibiotics. Multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are particularly concerning due to their high morbidity and mortality rates. In this context, endolysins, derived from bacteriophages, offer a promising alternative to traditional antibiotics. This study introduces LysJEP8, a novel endolysin derived from Escherichia phage JEP8, which exhibits remarkable antimicrobial activity against key Gram-negative members of the ESKAPE group. Comparative assessments highlight LysJEP8's superior performance in reducing bacterial survival rates compared to previously described endolysins, with the most significant impact observed against P. aeruginosa, and notable effects on A. baumannii and K. pneumoniae. The study found that LysJEP8, as predicted by in silico analysis, worked best at lower pH values but lost its effectiveness at salt concentrations close to physiological levels. Importantly, LysJEP8 exhibited remarkable efficacy in the disruption of P. aeruginosa biofilms. This research underscores the potential of LysJEP8 as a valuable candidate for the development of innovative antibacterial agents, particularly against Gram-negative pathogens, and highlights opportunities for further engineering and optimization to address AMR effectively., The authors are indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. The authors acknowledge financial support from the Agencia Española de Investigación for the granted projects (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EG-F and AA, and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NF-M) and to AGAUR for project 2021 SGR 01552. JVC is supported with a Margarita Salas grant for the training of young doctoral graduates (grant no. 722713)., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Lactiplantibacillus plantarum: a new example of inclusion body producing bacteria

  • Baltà, Ricardo
  • Serrano-Adrover, Caterina
  • López-Cano, Adrià
  • Gifre-Renom, Laia
  • Sanchez-Chardi, Alejandro
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
Background Lactic Acid Bacteria such as Lactococcus lactis, Latilactobacillus sakei (basonym: Lactobacillus sakei) and Lactiplantibacillus plantarum (basonym: Lactobacillus plantarum) have gained importance as recombinant cell factories. Although it was believed that proteins produced in these lipopolysaccharides (LPS)-free microorganisms do not aggregate, it has been shown that L. lactis produce inclusion bodies (IBs) during the recombinant production process. These protein aggregates contain biologically active protein, which is slowly released, being a biomaterial with a broad range of applications including the obtainment of soluble protein. However, the aggregation phenomenon has not been characterized so far in L. plantarum. Thus, the current study aims to determine the formation of protein aggregates in L. plantarum and evaluate their possible applications. Results To evaluate the formation of IBs in L. plantarum, the catalytic domain of bovine metalloproteinase 9 (MMP-9cat) protein has been used as model protein, being a prone-to-aggregate (PTA) protein. The electron microscopy micrographs showed the presence of electron-dense structures in L. plantarum cytoplasm, which were further purified and analyzed. The ultrastructure of the isolated protein aggregates, which were smooth, round and with an average size of 250–300 nm, proved that L. plantarum also forms IBs under recombinant production processes of PTA proteins. Besides, the protein embedded in these aggregates was fully active and had the potential to be used as a source of soluble protein or as active nanoparticles. The activity determination of the soluble protein solubilized from these IBs using non-denaturing protocols proved that fully active protein could be obtained from these protein aggregates. Conclusions These results proved that L. plantarum forms aggregates under recombinant production conditions. These aggregates showed the same properties as IBs formed in other expression systems such as Escherichia coli or L. lactis. Thus, this places this LPS-free microorganism as an interesting alternative to produce proteins of interest for the biopharmaceutical industry, which are obtained from the IBs in an important number of cases., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins

  • López-Cano, Adrià
  • Ferrer-Miralles, Neus
  • Sánchez, Julieta
  • Carratalá, Jose Vicente
  • Rodriguez Rodriguez, Xavier
  • Ratera, Imma
  • Guasch, Judith
  • Pich, Oscar Q.
  • Bierge, Paula
  • Garcia-de-la-Maria, Cristina
  • Miro, Jose M.
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Time to consider ruling out inclusion bodies denaturing protocols for spontaneous solubilization of biologically active proteins

  • Baltà, Ricardo
  • Garcia-Fruitos, Elena
  • Arís, Anna
The formation of inclusion bodies (IBs) in microbial cell factories is a very common process occurring during recombinant protein production. Different protocols have been developed for the extraction of soluble proteins from IBs using several strategies, ranging from the use of harsh denaturing and high concentrations of chaotropic agents and reducing agents to the use of mild protocols based on the use of non-denaturing detergents. However, in recent years, the biological vision of IBs has changed and research studies have demonstrated that these protein aggregates contain biologically active and properly folded recombinant proteins. This drives us to redefine the methodologies currently used to obtain soluble protein using IB as a protein source. Hence, we propose the extraction of IB protein via the simple spontaneous solubilization of IB as a strategy broadly applicable to all kinds of recombinant proteins without the negative effects of detergents and chaotropic agents on final biological activity. We prove the wide applicability of spontaneous solubilization processes to different types of IBs and that protocols can be easily customized for each protein in terms of timing and incubation temperature by monitoring the protein activity of the solubilized fraction., Ministerio de Ciencia,Innovación y Universidades, Grants PID2019-107298RB-C21/AEI/10.13039/ 501100011033, AGAUR,2021 SGR 01552., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring the impact of the recombinant Escherichia coli strain on defensins antimicrobial activity: BL21 versus Origami strain

  • López Cano, Adrià
  • Martínez Miguel, Marc
  • Guasch, Judit
  • Ratera, Immaculada
  • Arís, Anna
  • Garcia Fruitós, Elena
The growing emergence of microorganisms resistant to antibiotics has prompted the development of alternative antimicrobial therapies. Among them, the antimicrobial peptides produced by innate immunity, which are also known as host defense peptides (HDPs), hold great potential. They have been shown to exert activity against both Gram-positive and Gram-negative bacteria, including those resistant to antibiotics. These HDPs are classified into three categories: defensins, cathelicidins, and histatins. Traditionally, HDPs have been chemically synthesized, but this strategy often limits their application due to the high associated production costs. Alternatively, some HDPs have been recombinantly produced, but little is known about the impact of the bacterial strain in the recombinant product. This work aimed to assess the influence of the Escherichia coli strain used as cell factory to determine the activity and stability of recombinant defensins, which have 3 disulfide bonds. For that, an α-defensin [human α-defensin 5 (HD5)] and a β-defensin [bovine lingual antimicrobial peptide (LAP)] were produced in two recombinant backgrounds. The first one was an E. coli BL21 strain, which has a reducing cytoplasm, whereas the second was an E. coli Origami B, that is a strain with a more oxidizing cytoplasm. The results showed that both HD5 and LAP, fused to Green Fluorescent Protein (GFP), were successfully produced in both BL21 and Origami B strains. However, differences were observed in the HDP production yield and bactericidal activity, especially for the HD5-based protein. The HD5 protein fused to GFP was not only produced at higher yields in the E. coli BL21 strain, but it also showed a higher quality and stability than that produced in the Origami B strain. Hence, this data showed that the strain had a clear impact on both HDPs quantity and quality., This work was funded by Ministerio de Ciencia, Innovación y Universidades Grants (PID2019-107298RB-C21) to AA and EG-F, PID2019-105622RB-I00 to IR and through the ‘‘Severo Ochoa’’ Programme for Centers of Excellence in R&D (FUNFUTURE CEX2019-000917-S and SEV-2017-0706). The authors are also grateful to Marató de TV3 foundation for the Grant 201812-30-31-32-33 to EG-F and IR, and the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). AL-C received a pre-doctoral fellowship from Generalitat de Catalunya (FI-AGAUR), EG-F a post-doctoral fellowship from INIA and JG a Ramón y Cajal fellowship from MINN (RyC-2017-22614)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel generation of tailored antimicrobial drugs based on recombinant multidomain proteins

  • López Cano, Adrià
  • Ferrer Miralles, Neus
  • Sánchez, Julieta
  • Carratalá, Jose Vicente
  • Rodríguez Rodríguez, Xavier
  • Ratera, Immaculada
  • Guasch, Judit
  • Pich, Oscar Q.
  • Bierge, Paula
  • Garcia de la María, Cristina
  • Miro, Jose M.
  • García Fruitós, Elena
  • Arís, Anna
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means., This work was funded by the Ministerio de Ciencia, Innovación y Universidades grants (PID2019-107298RB-C21/AEI/10.13039/501100011033; PID2019-105622RBI00; PID2020-115296RA-I00; RYC-2017-22614), by Marató de TV3 foundation (201812-30-31-32-33). We also thank the Instituto de Salud Carlos III (ISCIII) through the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). The authors are also indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. JMS is supported with a María Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (“Financed by European Union-Next GenerationEU”). AL-C received a pre-doctoral fellowship from Generalitat de Catalunya (FI-AGAUR) and EG-F a post-doctoral fellowship from INIA (DOC-INIA). J.G. acknowledges financial support from the Max Planck Society through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy” in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). ICMAB acknowledges support from the MICINN through the ‘‘Severo Ochoa’’ Program for Centers of Excellence in R&D (CEX2019-000917-S). JMM received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–23., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2019-000917-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The future of recombinant host defense peptides

  • Roca-Pinilla, Ramon
  • Lisowski, Leszek
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
The antimicrobial resistance crisis calls for the discovery and production of new antimicrobials. Host defense peptides (HDPs) are small proteins with potent antibacterial and immunomodulatory activities that are attractive for translational applications, with several already under clinical trials. Traditionally, antimicrobial peptides have been produced by chemical synthesis, which is expensive and requires the use of toxic reagents, hindering the large-scale development of HDPs. Alternatively, HDPs can be produced recombinantly to overcome these limitations. Their antimicrobial nature, however, can make them toxic to the hosts of recombinant production. In this review we explore the different strategies that are used to fine-tune their activities, bioengineer them, and optimize the recombinant production of HDPs in various cell factories., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Design strategies for positively charged endolysins: Insights into Artilysin development

  • Carratalá, Jose Vicente
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
  • Ferrer-Miralles, Neus
Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature., The authors are indebted to Agencia Española de Investigación for the granted project (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EGF and AA and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NFM), to Marató de TV3 foundation (grant 201812-30-31-32-33) and to AGAUR for project 2021 SGR 01552. The authors are also indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. JVCT is supported with a Margarita Salas grant for the training of young doctoral graduates (722713)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Time to consider ruling out inclusion bodies denaturing protocols for spontaneous solubilization of biologically active proteins

  • Baltà, Ricardo
  • Garcia-Fruitos, Elena
  • Arís, Anna
The formation of inclusion bodies (IBs) in microbial cell factories is a very common process occurring during recombinant protein production. Different protocols have been developed for the extraction of soluble proteins from IBs using several strategies, ranging from the use of harsh denaturing and high concentrations of chaotropic agents and reducing agents to the use of mild protocols based on the use of non-denaturing detergents. However, in recent years, the biological vision of IBs has changed and research studies have demonstrated that these protein aggregates contain biologically active and properly folded recombinant proteins. This drives us to redefine the methodologies currently used to obtain soluble protein using IB as a protein source. Hence, we propose the extraction of IB protein via the simple spontaneous solubilization of IB as a strategy broadly applicable to all kinds of recombinant proteins without the negative effects of detergents and chaotropic agents on final biological activity. We prove the wide applicability of spontaneous solubilization processes to different types of IBs and that protocols can be easily customized for each protein in terms of timing and incubation temperature by monitoring the protein activity of the solubilized fraction., Ministerio de Ciencia,Innovación y Universidades, Grants PID2019-107298RB-C21/AEI/10.13039/ 501100011033, AGAUR,2021 SGR 01552., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exploring the therapeutic potential of recombinant bovine β-defensins for antimicrobial and anti-inflammatory functions in sepsis management

  • Saubi, Cristina
  • Baltà-Foix, Ricardo
  • Carratalá, Jose Vicente
  • Fàbregas, Francesc
  • Sandín, Daniel
  • Torrent, Marc
  • Garcia-Fruitos, Elena
  • Arís, Anna
β-defensins are multifunctional peptides of the host immune system involved in responses to infectious diseases. We investigated the potential of five recombinant proteins based on bovine β-defensins (bovine neutrophil β-defensins (BNBD) 1, 2, 3, and 4, and the tracheal antimicrobial peptide (TAP)) in functions relevant to sepsis such as antimicrobial activity, lipopolysaccharide (LPS) binding and neutralisation, and the stimulation of cytokine response in epithelial cells. These β-defensins were produced in Lactococcus lactis as fusion proteins. Antimicrobial activity was tested against Escherichia coli; LPS binding and neutralisation were assessed using a fluorescent probe displacement assay and by measuring tumour necrosis factor alpha (TNFα) levels in whole blood after an LPS challenge, respectively. Interleukin-8 (IL-8) levels were quantified to evaluate the epithelial immune response. All β-defensins exhibited different properties, suggesting they may have distinct mechanisms and functions in resolving infections. The recombinant BNBD4 showed potent antimicrobial activity against E. coli, whereas TAP was more notable for its ability to bind and neutralise LPS. These findings suggest that β-defensins, particularly BNBD4 and TAP, may be utilised to treat sepsis by targeting bacterial pathogens and modulating inflammatory responses., This work was funded by Ministerio de Ciencia, Innovación y Universidades Grants PID2019-107298RB-C21/AEI/10.13039/ 501100011033) to AA and EG-F and by MICIU/AEI/10.13039/ 501100011033 and FEDER with project PID2023-152706OB-I00. CS and RB-F received a pre-doctoral fellowship from Generalitat de Catalunya (FI-AGAUR and INIA (FPI-INIA, MINECO), respectively. DS received a pre-doctoral fellowship PRE2018-083243 from Ministerio de Ciencia, Innovación y Universidades. JVC was supported with a Margarita Salas grant for the training of young doctoral graduates (Grant No. 722713)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quality comparison of recombinant soluble proteins and proteins solubilized from bacterial inclusion bodies

  • López-Cano, Adrià
  • Sicilia, Paula
  • Gaja, Clara
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
Recombinant protein production in bacteria is often accompanied by the formation of aggregates, known as inclusion bodies (IBs). Although several strategies have been developed to minimize protein aggregation, many heterologous proteins are produced in aggregated form. For these proteins, purification necessarily requires processes of solubilization and refolding, often involving denaturing agents. However, the presence of biologically active recombinant proteins forming IBs has driven a redefinition of the protocols used to obtain soluble protein avoiding the protein denaturation step. Among the different strategies described, the detergent n-lauroylsarcosine (NLS) has proved to be effective. However, the impact of the NLS on final protein quality has not been evaluated so far. Here, the activity of three antimicrobial proteins (all as GFP fusions) obtained from the soluble fraction was compared with those solubilized from IBs. Results showed that NLS solubilized proteins from IBs efficiently, but that protein activity was impaired. Thus, a solubilization protocol without detergents was evaluated, demonstrating that this strategy efficiently solubilized proteins embedded in IBs while retaining their biological activity. These results showed that the protocol used for IB solubilization has an impact on final protein quality and that IBs can be solubilized through a very simple step, obtaining fully active proteins., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Structure–Antimicrobial Activity Relationships of Recombinant Host Defence Peptides Against Drug-Resistant Bacteria

  • Travé-Asensio, Sergi
  • Tort-Miró, Aida
  • Pinheiro, Silvana
  • Garcia-Fruitos, Elena
  • Arís, Anna
  • Zamora, William J.
Host defence peptides (HDPs) represent a valuable class of antimicrobial agents with the potential to address the growing threat of antimicrobial resistance (AMR). Here, we have studied recombinant constructs based on a combination of HDPs fused to the GFP protein and multidomain proteins combining three or four HDPs in a single polypeptide, referred to as first and second generation antimicrobials, respectively. These recombinant peptides were tested against Gram-positive and Gram-negative bacteria associated with healthcare infections. In addition, in silico studies provided insight into the antimicrobial structure–activity relationships of these biomolecules. For the first generation of antimicrobials, amphipathicity mainly explains the average antimicrobial activity against the Gram-positive strains. In the case of the Gram-negative bacteria, it depends on the quantity and the exposed area of the Ser and Thr amino acids. For the second generation of antimicrobials, the order of domains is crucial to act against Gram-positive strains, preferably by positioning the most bioactive domain against the Gram-positive pathogen at the ends., This work was supported by the AGAUR (Generalitat de Catalunya), 2021SGR01552, Ministerio de Universidades, FPU21/04977, Ministerio de Ciencia, Innovación y Universidades, PID2019-107298RB-C21/AEI/10.13039/501100011033, PID2022-136521OB-I00 and Vice Chancellor for Research of the University of Costa Rica, 115-C1-450., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins

  • López-Cano, Adrià
  • Ferrer-Miralles, Neus
  • Sánchez, Julieta
  • Carratalá, Jose Vicente
  • Rodriguez Rodriguez, Xavier
  • Ratera, Imma
  • Guasch, Judith
  • Pich, Oscar Q.
  • Bierge, Paula
  • Garcia-de-la-Maria, Cristina
  • Miro, Jose M.
  • Garcia-Fruitos, Elena
  • Alomar, Oscar
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exploring the impact of the recombinant Escherichia coli strain on defensins antimicrobial activity: BL21 versus Origami strain

  • López-Cano, Adrià
  • Martínez-Miguel, Marc
  • Guasch, Judith
  • Ratera, Imma
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
The growing emergence of microorganisms resistant to antibiotics has prompted the development of alternative antimicrobial therapies. Among them, the antimicrobial peptides produced by innate immunity, which are also known as host defense peptides (HDPs), hold great potential. They have been shown to exert activity against both Gram-positive and Gram-negative bacteria, including those resistant to antibiotics. These HDPs are classified into three categories: defensins, cathelicidins, and histatins. Traditionally, HDPs have been chemically synthesized, but this strategy often limits their application due to the high associated production costs. Alternatively, some HDPs have been recombinantly produced, but little is known about the impact of the bacterial strain in the recombinant product. This work aimed to assess the influence of the Escherichia coli strain used as cell factory to determine the activity and stability of recombinant defensins, which have 3 disulfide bonds. For that, an α-defensin [human α-defensin 5 (HD5)] and a β-defensin [bovine lingual antimicrobial peptide (LAP)] were produced in two recombinant backgrounds. The first one was an E. coli BL21 strain, which has a reducing cytoplasm, whereas the second was an E. coli Origami B, that is a strain with a more oxidizing cytoplasm. The results showed that both HD5 and LAP, fused to Green Fluorescent Protein (GFP), were successfully produced in both BL21 and Origami B strains. However, differences were observed in the HDP production yield and bactericidal activity, especially for the HD5-based protein. The HD5 protein fused to GFP was not only produced at higher yields in the E. coli BL21 strain, but it also showed a higher quality and stability than that produced in the Origami B strain. Hence, this data showed that the strain had a clear impact on both HDPs quantity and quality., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lactiplantibacillus plantarum: a new example of inclusion body producing bacteria

  • Baltà, Ricardo
  • Serrano-Adrover, Caterina
  • López-Cano, Adrià
  • Gifre-Renom, Laia
  • Sanchez-Chardi, Alejandro
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
Background Lactic Acid Bacteria such as Lactococcus lactis, Latilactobacillus sakei (basonym: Lactobacillus sakei) and Lactiplantibacillus plantarum (basonym: Lactobacillus plantarum) have gained importance as recombinant cell factories. Although it was believed that proteins produced in these lipopolysaccharides (LPS)-free microorganisms do not aggregate, it has been shown that L. lactis produce inclusion bodies (IBs) during the recombinant production process. These protein aggregates contain biologically active protein, which is slowly released, being a biomaterial with a broad range of applications including the obtainment of soluble protein. However, the aggregation phenomenon has not been characterized so far in L. plantarum. Thus, the current study aims to determine the formation of protein aggregates in L. plantarum and evaluate their possible applications. Results To evaluate the formation of IBs in L. plantarum, the catalytic domain of bovine metalloproteinase 9 (MMP-9cat) protein has been used as model protein, being a prone-to-aggregate (PTA) protein. The electron microscopy micrographs showed the presence of electron-dense structures in L. plantarum cytoplasm, which were further purified and analyzed. The ultrastructure of the isolated protein aggregates, which were smooth, round and with an average size of 250–300 nm, proved that L. plantarum also forms IBs under recombinant production processes of PTA proteins. Besides, the protein embedded in these aggregates was fully active and had the potential to be used as a source of soluble protein or as active nanoparticles. The activity determination of the soluble protein solubilized from these IBs using non-denaturing protocols proved that fully active protein could be obtained from these protein aggregates. Conclusions These results proved that L. plantarum forms aggregates under recombinant production conditions. These aggregates showed the same properties as IBs formed in other expression systems such as Escherichia coli or L. lactis. Thus, this places this LPS-free microorganism as an interesting alternative to produce proteins of interest for the biopharmaceutical industry, which are obtained from the IBs in an important number of cases., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria

  • Carratalá, Jose Vicente
  • Ferrer‐Miralles, Neus
  • Garcia-Fruitos, Elena
  • Arís, Anna
Antimicrobial resistance (AMR) is an escalating global health crisis, driven by the overuse and misuse of antibiotics. Multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are particularly concerning due to their high morbidity and mortality rates. In this context, endolysins, derived from bacteriophages, offer a promising alternative to traditional antibiotics. This study introduces LysJEP8, a novel endolysin derived from Escherichia phage JEP8, which exhibits remarkable antimicrobial activity against key Gram-negative members of the ESKAPE group. Comparative assessments highlight LysJEP8's superior performance in reducing bacterial survival rates compared to previously described endolysins, with the most significant impact observed against P. aeruginosa, and notable effects on A. baumannii and K. pneumoniae. The study found that LysJEP8, as predicted by in silico analysis, worked best at lower pH values but lost its effectiveness at salt concentrations close to physiological levels. Importantly, LysJEP8 exhibited remarkable efficacy in the disruption of P. aeruginosa biofilms. This research underscores the potential of LysJEP8 as a valuable candidate for the development of innovative antibacterial agents, particularly against Gram-negative pathogens, and highlights opportunities for further engineering and optimization to address AMR effectively., The authors are indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. The authors acknowledge financial support from the Agencia Española de Investigación for the granted projects (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EG-F and AA, and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NF-M) and to AGAUR for project 2021 SGR 01552. JVC is supported with a Margarita Salas grant for the training of young doctoral graduates (grant no. 722713)., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel Generation of Tailored Antimicrobial Drugs Based on Recombinant Multidomain Proteins

  • López-Cano, Adrià
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Rodriguez Rodriguez, Xavier
  • Ratera Bastardas, Imma|||0000-0002-1464-9789
  • Guasch, Judith|||0000-0002-3571-4711
  • Pich, Oscar Q.|||0000-0003-3561-630X
  • Bierge, Paula|||0000-0003-0917-3445
  • García de la Mària, Cristina|||0000-0002-0585-9469
  • Miró, José M.|||0000-0001-8057-7755
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
Antibiotic resistance has exponentially increased during the last years. It is necessary to develop new antimicrobial drugs to prevent and treat infectious diseases caused by multidrug- or extensively-drug resistant (MDR/XDR)-bacteria. Host Defense Peptides (HDPs) have a versatile role, acting as antimicrobial peptides and regulators of several innate immunity functions. The results shown by previous studies using synthetic HDPs are only the tip of the iceberg, since the synergistic potential of HDPs and their production as recombinant proteins are fields practically unexplored. The present study aims to move a step forward through the development of a new generation of tailored antimicrobials, using a rational design of recombinant multidomain proteins based on HDPs. This strategy is based on a two-phase process, starting with the construction of the first generation molecules using single HDPs and further selecting those HDPs with higher bactericidal efficiencies to be combined in the second generation of broad-spectrum antimicrobials. As a proof of concept, we have designed three new antimicrobials, named D5L37βD3, D5L37D5L37 and D5LAL37βD3. After an in-depth exploration, we found D5L37D5L37 to be the most promising one, since it was equally effective against four relevant pathogens in healthcare-associated infections, such as methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis (MRSE) and MDR Pseudomonas aeruginosa, being MRSA, MRSE and P. aeruginosa MDR strains. The low MIC values and versatile activity against planktonic and biofilm forms reinforce the use of this platform to isolate and produce unlimited HDP combinations as new antimicrobial drugs by effective means.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring the impact of the recombinant Escherichia coli strain on defensins antimicrobial activity, BL21 versus Origami strain

  • López-Cano, Adrià
  • Martínez-Miguel, Marc
  • Guasch, Judith|||0000-0002-3571-4711
  • Ratera Bastardas, Imma|||0000-0002-1464-9789
  • Arís i Giralt, Anna|||0000-0001-7830-888X
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
The growing emergence of microorganisms resistant to antibiotics has prompted the development of alternative antimicrobial therapies. Among them, the antimicrobial peptides produced by innate immunity, which are also known as host defense peptides (HDPs), hold great potential. They have been shown to exert activity against both Gram-positive and Gram-negative bacteria, including those resistant to antibiotics. These HDPs are classified into three categories: defensins, cathelicidins, and histatins. Traditionally, HDPs have been chemically synthesized, but this strategy often limits their application due to the high associated production costs. Alternatively, some HDPs have been recombinantly produced, but little is known about the impact of the bacterial strain in the recombinant product. This work aimed to assess the influence of the Escherichia coli strain used as cell factory to determine the activity and stability of recombinant defensins, which have 3 disulfide bonds. For that, an α-defensin [human α-defensin 5 (HD5)] and a β-defensin [bovine lingual antimicrobial peptide (LAP)] were produced in two recombinant backgrounds. The first one was an E. coli BL21 strain, which has a reducing cytoplasm, whereas the second was an E. coli Origami B, that is a strain with a more oxidizing cytoplasm. The results showed that both HD5 and LAP, fused to Green Fluorescent Protein (GFP), were successfully produced in both BL21 and Origami B strains. However, differences were observed in the HDP production yield and bactericidal activity, especially for the HD5-based protein. The HD5 protein fused to GFP was not only produced at higher yields in the E. coli BL21 strain, but it also showed a higher quality and stability than that produced in the Origami B strain. Hence, this data showed that the strain had a clear impact on both HDPs quantity and quality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design strategies for positively charged endolysins, Insights into Artilysin development

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Arís i Giralt, Anna|||0000-0001-7830-888X
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LysJEP8, A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
Antimicrobial resistance (AMR) is an escalating global health crisis, driven by the overuse and misuse of antibiotics. Multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are particularly concerning due to their high morbidity and mortality rates. In this context, endolysins, derived from bacteriophages, offer a promising alternative to traditional antibiotics. This study introduces LysJEP8, a novel endolysin derived from Escherichia phage JEP8, which exhibits remarkable antimicrobial activity against key Gram-negative members of the ESKAPE group. Comparative assessments highlight LysJEP8's superior performance in reducing bacterial survival rates compared to previously described endolysins, with the most significant impact observed against P. aeruginosa, and notable effects on A. baumannii and K. pneumoniae. The study found that LysJEP8, as predicted by in silico analysis, worked best at lower pH values but lost its effectiveness at salt concentrations close to physiological levels. Importantly, LysJEP8 exhibited remarkable efficacy in the disruption of P. aeruginosa biofilms. This research underscores the potential of LysJEP8 as a valuable candidate for the development of innovative antibacterial agents, particularly against Gram-negative pathogens, and highlights opportunities for further engineering and optimization to address AMR effectively.